Series A

Acumen is a venture philanthropy organization that invests in visionary entrepreneurs building transformational companies from seed to scale. They focus on funding bold entrepreneurs who are creating inclusive solutions across sectors like sustainable agriculture, quality education, renewable energy, healthy communities, dignified jobs, and gender equality. Their mission is to break the cycle of poverty through patient capital investments in high-innovation, high-impact enterprises. They operate by deploying philanthropic capital to shape markets and support entrepreneurs who are addressing the world's toughest poverty-related challenges, investing where traditional funders won't. Acumen Ventures has established itself as a significant force in the impact investing ecosystem since 2001, with an A to Z directory of portfolio companies spanning over two decades. They matter because they've reinvented the rules of return, prioritizing impact alongside financial sustainability and helping to demonstrate that venture philanthropy can drive meaningful systemic change in underserved communities globally.

Alante Capital is an early-stage venture capital fund that invests in climate tech, deep tech, AI and enterprise software companies focused on modernizing the fashion, home and outdoor industries. They back innovation that reduces carbon emissions and brings circularity to these consumer industries that collectively represent a $4 trillion market. Founded by Karla and Leslie, Alante was created to enable investors, entrepreneurs and business leaders to come together and reimagine the future of industry while finding solutions to pressing global problems and addressing climate change. They work across the entire value chain with a diversified approach, investing in technologies that transform how products are designed, made, sold, used and recovered. Alante addresses critical challenges in often-overlooked yet ubiquitous industries where overconsumption has resulted in staggering waste, opaque supply chains have enabled forced labor and hazardous conditions, and record-low prices have increased environmental and social costs exponentially. They believe in achieving transformative impact without compromising returns, helping companies integrate solutions that make industry lifecycles safer, cleaner, more efficient and more sustainable.

Angelini Ventures is the venture capital arm of Angelini Industries, investing in innovative startups across biotech and digital health. The firm focuses on advancing healthcare through breakthrough therapies, medical technologies, and data-driven solutions. With a global investment strategy, Angelini Ventures backs early and growth-stage companies working to improve patient outcomes and transform how diseases are treated and managed. The firm combines capital with deep industry expertise and strategic support from its parent organization.

Astanor Ventures is an impact investor that transforms the agrifood system by fostering innovation from "soil and sea to gut." They operate two complementary investment strategies - Astanor Venture for early-stage companies and Astanor Growth for scaling businesses across the entire agrifood value chain. Their mission centers on building a more resilient planet by investing at the intersection of planetary and human health, using food and agricultural systems as primary levers for change. They support ambitious entrepreneurs developing globally scalable solutions capable of driving systemic change, reconnecting planetary and human health through better nutrition and sustainable farming practices. As a global leader in impact investing, Astanor plays a crucial role in financing and scaling systemic disruption needed to reach ambitious targets set by the Paris Agreement and UN SDGs. With offices across Europe and the US, they demonstrate that there is no trade-off between return and impact - the more successful their portfolio businesses become, the greater the positive impact on both people and the planet.

Avaana Capital is an India-based venture capital firm investing in climate and sustainability solutions across sectors such as energy, mobility, agriculture, and industrial systems. The firm backs early-stage founders building scalable technologies that address climate change while driving economic growth. Co-founded by Anjali Bansal, Avaana combines deep operational expertise with a strong network across government, corporates, and global investors. The firm focuses on enabling the transition to a low-carbon economy through innovation and technology.

Beyond Impact is an impact investment firm focused on accelerating the transition to a more sustainable, animal-free economy. Founded in 2017, the firm backs companies developing alternatives to animal-based products across food, materials, pharmaceuticals, and consumer goods. The firm’s mission centers on building a “kinder, cleaner, healthier world” by investing in scalable businesses that reduce environmental damage, eliminate animal suffering, and improve human health. Its portfolio targets high-growth sectors such as plant-based foods, alternative proteins, and next-generation biomaterials.

The Catalyst Fund is a pre-seed VC fund and accelerator that invests $200K in early-stage startups and follows on at Seed and Series A rounds. As a thesis-driven investor, they focus exclusively on backing founders building climate adaptation and resilience solutions across Africa. The fund operates as both an investor and venture builder, with ex-founders and operators providing hands-on support spending 400+ hours with each startup to accelerate growth. Since 2015, they have accelerated 81 companies across 19 markets, connecting startups to their global network of 250+ investors and ecosystem partners. Their comprehensive approach includes tailored venture building support across key business areas including data, tech, sales, talent, product, fundraising, and growth.

ReGen Ventures is an impact-focused venture capital firm that invests in foundational regenerative technologies designed to power a future of abundance. They focus on four core investment areas: clean energy, planetary intelligence, programmable matter, and adaptive robotics, partnering with founders who are building transformative technologies from the atomic to planetary scale. The firm operates with a mission to reimagine the world by supporting technologies that make regeneration inevitable, enabling infinite growth and prosperity on a finite planet. They take a hands-on approach with founders, providing comprehensive support that ranges from business modeling to personal wellness, emphasizing long-term sustainable returns over short-term wins. ReGen Ventures positions itself as an innovator in the investment space, paving a new path for what investments should be by focusing on root causes rather than symptoms of environmental challenges. They are building what they call a "ReGenerative Future" where climate change is reframed as an opportunity for transformation, backing founders with unreasonable ambition who alter understanding of what's possible in addressing planetary challenges.

T1D Fund is the world's first scaled venture fund dedicated exclusively to type 1 diabetes, operating as an impact investment fund that supports promising companies through equity investments and expertise. They focus specifically on accelerating treatments, prevention, and cures for the approximately 9 million people living with T1D globally. The fund operates as a powerful platform for collaboration, using catalytic capital and expertise to de-risk investments and create a flywheel effect that attracts other investors to the T1D space. As a wholly owned, not-for-profit independently run subsidiary of Breakthrough T1D, they leverage their intellectual capital and expert network to offer comprehensive support to portfolio companies, steering them through regulatory, clinical, and commercial milestones. With over $200 million in assets under management and 25+ active portfolio companies, T1D Fund creates significant impact in the diabetes ecosystem by reinvesting 100% of returns to propel continuous progress. Their unique position as subject matter experts combined with access to Breakthrough T1D's extensive network of research, clinical, and medical expertise enables them to transform the landscape of T1D investment and accelerate the development of life-changing therapies.